¹Ì±¹ÀÇ ÀúºÐÀÚ Çõ½Å API CDMO ½ÃÀå : ½ÃÀå ±Ô¸ð, Á¡À¯À², µ¿Ç⠺м® - º´±âº°, ¼­ºñ½ºº°, °í°´ À¯Çüº°, Ä¡·á ¿µ¿ªº°, Áö¿ªº°, ºÎ¹®º° ¿¹Ãø(2025-2030³â)
U.S. Small Molecule Innovator API CDMO Market Size, Share & Trends Analysis Report By Stage Type (Preclinical, Clinical, Commercial), By Service, By Customer Type, By Therapeutic Area, By Region, And Segment Forecasts, 2025 - 2030
»óǰÄÚµå : 1726377
¸®¼­Ä¡»ç : Grand View Research, Inc.
¹ßÇàÀÏ : 2025³â 04¿ù
ÆäÀÌÁö Á¤º¸ : ¿µ¹® 120 Pages
 ¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
US $ 4,950 £Ü 6,857,000
Unprintable PDF & Excel (Single User License) help
º¸°í¼­ PDF ¹× ¿¢¼¿À» 1Àθ¸ »ç¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. ÅØ½ºÆ® µîÀÇ º¹»ç ¹× ºÙ¿©³Ö±â, Àμâ´Â ºÒ°¡´ÉÇÕ´Ï´Ù.
US $ 5,950 £Ü 8,242,000
Printable PDF & Excel (5-User License) help
º¸°í¼­ PDF ¹× ¿¢¼¿À» µ¿ÀÏ ±â¾÷ ³» µ¿ÀÏ ºÎ¼­¿¡¼­ ÃÖ´ë 5¸í±îÁö »ç¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. ÅØ½ºÆ® µîÀÇ º¹»ç ¹× ºÙ¿©³Ö±â, Àμâ´Â °¡´ÉÇÕ´Ï´Ù.
US $ 7,950 £Ü 11,013,000
Printable PDF & Excel (Enterprise License) help
º¸°í¼­ ±¸¸Å ±â¾÷ ¹× ±× ÀÚȸ»ç, °ü°è»ç°¡ »ç¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀ̸ç, PDF ¹× ¿¢¼¿ ÅØ½ºÆ® µîÀÇ º¹»ç ¹× ºÙ¿©³Ö±â, ÀμⰡ °¡´ÉÇÕ´Ï´Ù.


¤± Add-on °¡´É: °í°´ÀÇ ¿äû¿¡ µû¶ó ÀÏÁ¤ÇÑ ¹üÀ§ ³»¿¡¼­ CustomizationÀÌ °¡´ÉÇÕ´Ï´Ù. ÀÚ¼¼ÇÑ »çÇ×Àº ¹®ÀÇÇØ Áֽñ⠹ٶø´Ï´Ù.

Çѱ۸ñÂ÷

¹Ì±¹ÀÇ ÀúºÐÀÚ Çõ½Å API CDMO ½ÃÀå ¼ºÀå ¹× µ¿Çâ :

Grand View Research, Inc.ÀÇ ÃֽŠº¸°í¼­¿¡ µû¸£¸é ¹Ì±¹ÀÇ ÀúºÐÀÚ Çõ½Å API CDMO ½ÃÀå ±Ô¸ð´Â 2030³â±îÁö 126¾ï ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøµÇ¸ç, 2025-2030³â CAGRÀº 6.0%·Î ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.

Á¦¾à ±â¾÷ÀÇ ¾Æ¿ô¼Ò½Ì °æÇâ °íÁ¶, ÀúºÐÀÚ ÀǾàǰ¿¡ ´ëÇÑ ¼ö¿ä Áõ°¡, ÀÓ»ó½ÃÇèÀÇ ±ÞÁõÀÌ ¹Ì±¹ ½ÃÀå¿¡ ±àÁ¤ÀûÀÎ ¿µÇâÀ» ¹ÌÄ¥ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.

ÀúºÐÀÚ´Â ¼¼°èÀÇ »õ·Î¿î Ä¡·á °³¹ß¿¡ ÀÖ¾î Áß¿äÇÑ ¿ªÇÒÀ» °è¼ÓÇϰí ÀÖ½À´Ï´Ù. ƯÈ÷ ½ÅÈï±¹ ½ÃÀå¿¡¼­´Â Ư¼öÀǾàǰÀÌ ¹Ì±¹ÀǾàǰÀÇ ¼ºÀåÀ» Á¡Á¡ °ßÀÎÇÏ°Ô µÇ¾î ÀÖÀ¸¸ç, Ư¼öÀǾàǰ ¸ÅÃâÀÇ Àý¹Ý ÀÌ»óÀ» ÀúºÐÀÚ ÀǾàǰÀÌ Â÷ÁöÇϰí ÀÖ½À´Ï´Ù. °Ô´Ù°¡ È¿À²¼ºÀÇ Çâ»óµµ ÀǾàǰ ¾Æ¿ô¼Ò½ÌÀÇ Áß¿äÇÑ ÃßÁø·ÂÀÌ µÇ°í ÀÖ½À´Ï´Ù. ½Å¾àÀÇ ½ÃÀå µµÀÔÀ» ¼­µÎ¸£µµ·Ï Á¦¾àȸ»ç¿¡ ¿ä±¸µÇ´Â ¾Ð¹Ú°¨ÀÌ ³ô¾ÆÁö´Â °¡¿îµ¥ ¾Æ¿ô¼Ò½ÌÀº ÀǾàǰ °³¹ß ÇÁ·Î¼¼½º¸¦ °¡¼ÓÈ­ÇÏ´Â ¼Ö·ç¼ÇÀ¸·Î ¶°¿À¸£°í ÀÖ½À´Ï´Ù. CDMO´Â Àü¹® Áö½Ä, °æÇè, ÃÖ÷´Ü ¼³ºñ¸¦ Ȱ¿ëÇÏ¿© °íǰÁú ÀǾàǰÀÇ ½Å¼ÓÇϰí È¿À²ÀûÀÎ »ý»êÀ» ÃËÁøÇϰí Á¦¾à ±â¾÷ÀÌ °³¹ß ÀÏÁ¤À» ÁؼöÇÒ ¼ö ÀÖµµ·Ï ÇÕ´Ï´Ù.

Á¦¾à ¹× ¹ÙÀÌ¿ÀÅ×Å©³î·¯Áö ±â¾÷Àº Àü¹® Áö½ÄÀ» Ȱ¿ëÇϱâ À§ÇØ CDMO ¼­ºñ½º¸¦ ¼±ÅÃÇÏ´Â °ÍÀÌ ´Ã¾î³ª°í ÀÖ½À´Ï´Ù. CDMO´Â Á¦Á¶ ´É·ÂÀÇ À¯¿¬¼º°ú È®À强À» Á¦°øÇÏ¿© Á¦¾à»ç°¡ º¯È­ÇÏ´Â ½ÃÀåÀÇ ¼ö¿ä¿¡ ÀûÀÀÇÏ°í »õ·Î¿î Ä¡·á¹ý¿¡ ´ëÇØ ½ÃÀå ÅõÀÔ±îÁöÀÇ ½Ã°£À» ´ÜÃàÇÒ ¼ö ÀÖ°Ô ÇÕ´Ï´Ù. Àü¹® Áö½ÄÀÇ Á¦°øÀ̳ª Çö±Ý È帧 °ü¸®ÀÇ °³¼±¿¡ °¡¼¼ÇØ ¾Æ¿ô¼Ò½ÌÀº ÅõÀÚ ¸®½ºÅ©ÀÇ °æ°¨ µî Á¦Á¶¸é¿¡¼­µµ Å« ¸Þ¸®Æ®¸¦ °¡Á®¿É´Ï´Ù. ¾ó¸® ½ºÅ×ÀÌÁöÀÇ ±â¼úÀ̳ª Á¦Ç°¿¡¼­´Â °í°¡ÀÇ ÀÚ»ç Á¦Á¶ ´É·ÂÀ» È®¸³ÇÏ´Â °ÍÀº Á¦Ç° °³¹ß ´Ü°è¿¡¼­ Å« ¸®½ºÅ©¸¦ ¼ö¹ÝÇÕ´Ï´Ù. µ¿½Ã¿¡ ¾Æ¿ô¼Ò½ÌÀº À§Çè ȸÇÇÀÇ ´ë¾ÈÀ¸·Îµµ ±â´ÉÇÕ´Ï´Ù.

ÀúºÐÀÚ ¿ø·áÀÇ ¾Æ¿ô¼Ò½ÌÀº Á¦Ç° ½ÃÀå ¼ö¿ä°¡ È®¸³µÇ¾î ÀÌÇØµÉ ¶§±îÁö À¯È¿ÇÑ Àü·«À¸·Î ¼±È£µÇ°í ÀÖ½À´Ï´Ù. ¿¹¸¦ µé¾î 2022³â 5¿ù CDMOÀÎ ÇÇ¶ó¸»ÆÄ¸¶ ¸®¹ÌƼµåÀÇ ÆÄ¸¶ ¼Ö·ç¼Ç½º »ç¾÷Àº ¿ÂŸ¸®¿ÀÁÖ ¿À·Î¶ó °ÅÁ¡¿¡ »õ·Î¿î API ½Ã¼³À» °³¼³Çß½À´Ï´Ù. ÀÌ Ãֽſ¹ °øÀåÀº Á¶¾÷À» ½ÃÀÛÇÏ¿© Ãʱ⠻ý»êÀ» ¿Ï·áÇß½À´Ï´Ù.

¹Ì±¹ÀÇ ÀúºÐÀÚ Çõ½Å API CDMO ½ÃÀå : ºÐ¼® °³¿ä

¸ñÂ÷

Á¦1Àå ºÐ¼® ¹æ¹ý ¹× ¹üÀ§

Á¦2Àå ÁÖ¿ä ¿ä¾à

Á¦3Àå ½ÃÀåÀÇ º¯µ¿ ¿äÀÎ, °æÇâ ¹× ¹üÀ§

Á¦4Àå ¹Ì±¹ÀÇ ÀúºÐÀÚ Çõ½Å API CDMO ½ÃÀå : º´±âº° ÃßÁ¤ ¹× µ¿Ç⠺м®

Á¦5Àå ¹Ì±¹ÀÇ ÀúºÐÀÚ Çõ½Å API CDMO ½ÃÀå : ¼­ºñ½ºº° ÃßÁ¤ ¹× µ¿Ç⠺м®

Á¦6Àå ¹Ì±¹ÀÇ ÀúºÐÀÚ Çõ½Å API CDMO ½ÃÀå : °í°´ À¯Çüº° ÃßÁ¤ ¹× µ¿Ç⠺м®

Á¦7Àå ¹Ì±¹ÀÇ ÀúºÐÀÚ Çõ½Å API CDMO ½ÃÀå : Ä¡·á ¿µ¿ªº° ÃßÁ¤ ¹× µ¿Ç⠺м®

Á¦8Àå ¹Ì±¹ÀÇ ÀúºÐÀÚ Çõ½Å API CDMO ½ÃÀå : Áö¿ªº° ºñÁî´Ï½º ºÐ¼®

Á¦9Àå °æÀï ±¸µµ

AJY
¿µ¹® ¸ñÂ÷

¿µ¹®¸ñÂ÷

U.S. Small Molecule Innovator API CDMO Market Growth & Trends:

The U.S. small molecule innovator API CDMO market size is anticipated to reach USD 12.60 billion by 2030 and is projected to grow at a CAGR of 6.0% from 2025 to 2030, according to a new report by Grand View Research, Inc. Agrowing outsourcing trend among pharmaceutical companies, increasing demand for small molecule drugs, and surge in clinical trials are anticipated to influence the U.S. market positively.

Small molecules continue to play an important role in developing new treatments globally. Specialty medicines are increasingly driving U.S. pharmaceutical growth, particularly in developed markets, with small molecule applications accounting for over half of specialty sales. In addition, enhanced efficiency serves as another pivotal driver for pharmaceutical outsourcing. With mounting pressure on pharmaceutical companies to expedite the introduction of new drugs to the market, outsourcing emerges as a solution to accelerate the drug development process. Leveraging their expertise, experience, and cutting-edge equipment, CDMOs facilitate the swift & efficient production of high-quality drugs, enabling pharmaceutical firms to adhere to their development schedules.

The pharmaceutical/biotechnology companies increasingly opt for CDMO services to leverage their expertise. CDMOs offer flexibility & scalability in manufacturing capacity, allowing pharmaceutical companies to adapt to changing market demands and accelerate time to market for new therapies. In addition to providing extended expertise and assisting in improved cash flow management, outsourcing brings significant manufacturing advantages, including reducing investment risks. In the context of early-stage technologies and products, establishing expensive in-house capabilities entails substantial risks across the product development phases. At the same time, outsourcing serves as a risk-averse alternative.

The preference for outsourcing small molecule API has grown as an effective strategy until market demand for products becomes well-established and understood. For instance, in May 2022, Piramal Pharma Limited's Pharma Solutions business, a CDMO, inaugurated a new API facility at its site in Aurora, Ontario. This state-of-the-art plant has commenced operations & has completed its initial production runs.

U.S. Small Molecule Innovator API CDMO Market Report Highlights:

Table of Contents

Chapter 1. Methodology and Scope

Chapter 2. Executive Summary

Chapter 3. Market Variables, Trends, & Scope

Chapter 4. U.S. Small Molecule Innovator API CDMO Market: Stage Type Estimates & Trend Analysis

Chapter 5. U.S. Small Molecule Innovator API CDMO Market: Service Estimates & Trend Analysis

Chapter 6. U.S. Small Molecule Innovator API CDMO Market: Customer Type Estimates & Trend Analysis

Chapter 7. U.S. Small Molecule Innovator API CDMO Market: Therapeutic Area Estimates & Trend Analysis

Chapter 8. U.S. Small Molecule Innovator API CDMO Market: Regional Business Analysis

Chapter 9. Competitive Landscape

(ÁÖ)±Û·Î¹úÀÎÆ÷¸ÞÀÌ¼Ç 02-2025-2992 kr-info@giikorea.co.kr
¨Ï Copyright Global Information, Inc. All rights reserved.
PC¹öÀü º¸±â